A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
About this item
Full title
Author / Creator
Santini, V , Allione, B , Zini, G , Gioia, D , Lunghi, M , Poloni, A , Cilloni, D , Sanna, A , Masiera, E , Ceccarelli, M , Abdel-Wahab, O , Terenzi, A , Angelucci, E , Finelli, C , Onida, F , Pelizzari, A , Ferrero, D , Saglio, G , Figueroa, M and Levis, A
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS)/myeloproliferative neoplasms. Prognosis is poor and there is a lack of effective treatments. The hypomethylating agent decitabine has shown activity against MDS and elderly acute myeloid leukemia, but there is little data focusin...
Alternative Titles
Full title
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5808077
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5808077
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2017.186
